Skip to search formSkip to main contentSkip to account menu

lumiracoxib

Known as: 2-((2-chloro-6-Fluorophenyl)amino)-5-methylbenzeneacetic acid, 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid, Lumiracoxibum 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

COX 189Prexige

Broader (2)

Cyclooxygenase 2 InhibitorsDiclofenac
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Defects in mouse nephrogenesis induced by selective and non‐selective cyclooxygenase‐2 inhibitors
BACKGROUND AND PURPOSE Deletion of the cyclooxygenase‐2 (COX‐2) gene causes impairment of kidney development, but the effect of… 
2010
2010
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive…
Aims:  To examine whether the blood pressure (BP) profiles of lumiracoxib and high‐dose ibuprofen differed in patients treated… 
2009
2009
Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
Lumiracoxib is a selective cyclo-oxygenase 2 (COX-2) inhibitor used for symptomatic treatment of osteoarthritis and acute pain… 
Review
2007
Review
2007
Single dose oral lumiracoxib for postoperative pain.
BACKGROUND Lumiracoxib is a novel selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors have been developed to avoid COX… 
2007
2007
Cancer survival in UK is improving but could be better
Doctors, managers, and pressure groups have condemned the abuse of older people's human rights in hospitals and care homes, after… 
Review
2006
Review
2006
Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspects
Summary In the 1990s, the pharmaceutical industry developed selective COX-2 inhibitors (coxibs) as alternatives to conventional… 
Review
2005
Review
2005
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor
Although highly selective cyclooxygenase (COX)-2 inhibitors have been shown to be less toxic to the gastrointestinal tract than… 
2005
2005
Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low‐Dose Aspirin in Healthy Subjects
This randomized, double‐blind, placebo‐controlled study evaluated the pharmacodynamic effects of concomitant low‐dose aspirin and… 
2004
2004
Bankrolling stem-cell research with California dollars.
Keith R. Yamamoto discusses the $3 billion bond measure that will be put before the California voters to provide state funds for… 
2004
2004
Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects
This two‐way crossover study evaluated the effect of fluconazole on the pharmacokinetics and selective COX‐2 inhibition of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)